Abevilly's single monoclonal antibody has been approved for new indications in China.

On January 22nd, AbbVie announced that the National Medical Products Administration has officially approved the use of risankizumab for the treatment of adult patients with moderate to severe active ulcerative colitis who have had inadequate response, loss of response, or intolerance to conventional therapy or biological agents.